Caris (CAI) Reports Q1 2026 Earnings with Strong Revenue Growth and Operational Improvements
Caris reported strong financial results for the first quarter of 2026, including a significant increase in total revenue driven by clinical molecular profiling services. The company also noted improvements in gross margin and continued positive adjusted EBITDA.
Topics: adjusted EBITDA ASP growth clinical case volumes free cash flow gross margin improvement molecular profiling services revenue